These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29185991)

  • 1. Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
    Favié LM; Murk JL; Meijer A; Nijstad AL; van Maarseveen EM; Sikma MA
    Antivir Ther; 2018; 23(5):457-461. PubMed ID: 29185991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.
    Wang Y; Zhong W; Salam A; Tarning J; Zhan Q; Huang JA; Weng H; Bai C; Ren Y; Yamada K; Wang D; Guo Q; Fang Q; Tsutomu S; Zou X; Li H; Gillesen A; Castle L; Chen C; Li H; Zhen J; Lu B; Duan J; Guo L; Jiang J; Cao R; Fan G; Li J; Hayden FG; Wang C; Horby P; Cao B
    EBioMedicine; 2020 Dec; 62():103125. PubMed ID: 33232871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
    Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
    Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Favipiravir, a new concept of antiviral drug against influenza viruses].
    Reina J; Reina N
    Rev Esp Quimioter; 2017 Apr; 30(2):79-83. PubMed ID: 28176519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection.
    Wang Y; Fan G; Salam A; Horby P; Hayden FG; Chen C; Pan J; Zheng J; Lu B; Guo L; Wang C; Cao B
    J Infect Dis; 2020 Apr; 221(10):1688-1698. PubMed ID: 31822885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
    Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
    Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.
    Gowen BB; Sefing EJ; Westover JB; Smee DF; Hagloch J; Furuta Y; Hall JO
    Antiviral Res; 2015 Sep; 121():132-7. PubMed ID: 26186980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
    Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
    Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.
    Ormond L; Liu P; Matuszewski S; Renzette N; Bank C; Zeldovich K; Bolon DN; Kowalik TF; Finberg RW; Jensen JD; Wang JP
    Genome Biol Evol; 2017 Jul; 9(7):1913-1924. PubMed ID: 28854600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
    Rodríguez A; Díaz E; Martín-Loeches I; Sandiumenge A; Canadell L; Díaz JJ; Figueira JC; Marques A; Alvarez-Lerma F; Vallés J; Baladín B; García-López F; Suberviola B; Zaragoza R; Trefler S; Bonastre J; Blanquer J; Rello J;
    J Antimicrob Chemother; 2011 May; 66(5):1140-9. PubMed ID: 21385717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
    Cao RY; Xiao JH; Cao B; Li S; Kumaki Y; Zhong W
    Antivir Chem Chemother; 2014 Dec; 23(6):237-40. PubMed ID: 23948557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
    Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F;
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005389. PubMed ID: 28231247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.
    Kromdijk W; Sikma MA; van den Broek MP; Beijnen JH; Huitema AD; de Lange DW
    Intensive Care Med; 2013 May; 39(5):977-8. PubMed ID: 23443310
    [No Abstract]   [Full Text] [Related]  

  • 18. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned.
    Sürmelioğlu N; Demirtürk E; Ateş Ayhan N; Özel Yeşilyurt A; Bayrakçi S; Kaynak MS; Özyılmaz E; Allegaert K
    Int J Clin Pharmacol Ther; 2024 Aug; 62(8):345-352. PubMed ID: 38920081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
    Shiraki K; Daikoku T
    Pharmacol Ther; 2020 May; 209():107512. PubMed ID: 32097670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.
    Delang L; Abdelnabi R; Neyts J
    Antiviral Res; 2018 May; 153():85-94. PubMed ID: 29524445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.